{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T06:06:07Z","timestamp":1787897167142,"version":"build-2784847793"},"reference-count":39,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.ijantimicag.2017.10.010","type":"journal-article","created":{"date-parts":[[2017,10,27]],"date-time":"2017-10-27T20:15:16Z","timestamp":1509135316000},"page":"213-220","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Empirical treatment of lower urinary tract infections in the face of spreading multidrug resistance: in vitro study on the effectiveness of nitroxoline"],"prefix":"10.1016","volume":"51","author":[{"given":"A.","family":"Sobke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Makarewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Baier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"B\u00e4r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Pfister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.G.","family":"Gatermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.W.","family":"Pletz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Forstner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2017.10.010_bib0010","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/QCO.0000000000000228","article-title":"Global epidemiology of urinary tract infections","volume":"29","author":"Tandogdu","year":"2016","journal-title":"Curr Opin Infect Dis"},{"issue":"Suppl. 1A","key":"10.1016\/j.ijantimicag.2017.10.010_bib0015","doi-asserted-by":"crossref","first-page":"5S","DOI":"10.1016\/S0002-9343(02)01054-9","article-title":"Epidemiology of urinary tract infections: incidence, morbidity, and economic costs","volume":"113","author":"Foxman","year":"2002","journal-title":"Am J Med"},{"key":"10.1016\/j.ijantimicag.2017.10.010_bib0020","series-title":"Point prevalence survey of healthcare-associated infections and antimicrobial use in European long-term care facilities. ECDC surveillance report","author":"European Centre for Disease Prevention and Control (ECDC)","year":"2014"},{"key":"10.1016\/j.ijantimicag.2017.10.010_bib0025","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMcp1104429","article-title":"Clinical practice. Uncomplicated urinary tract infection","volume":"366","author":"Hooton","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2017.10.010_bib0030","doi-asserted-by":"crossref","first-page":"647","DOI":"10.3122\/jabfm.2011.06.100299","article-title":"Do urine cultures for urinary tract infections decrease follow-up visits?","volume":"24","author":"Johnson","year":"2011","journal-title":"J Am Board Fam Med"},{"key":"10.1016\/j.ijantimicag.2017.10.010_bib0035","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s00120-011-2512-z","article-title":"National S3 guideline on uncomplicated urinary tract infection: recommendations for treatment and management of uncomplicated community-acquired bacterial urinary tract infections in adult patients","volume":"50","author":"Wagenlehner","year":"2011","journal-title":"Urologe A"},{"key":"10.1016\/j.ijantimicag.2017.10.010_bib0040","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1086\/339812","article-title":"Empiric use of trimethoprim\u2013sulfamethoxazole (TMP-SMX) in the treatment of women with uncomplicated urinary tract infections, in a geographical area with a high prevalence of TMP-SMX-resistant uropathogens","volume":"34","author":"Raz","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.10.010_bib0045","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1086\/322603","article-title":"Empirical therapy for uncomplicated urinary tract infections in an era of increasing antimicrobial resistance: a decision and cost analysis","volume":"33","author":"Le","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.10.010_bib0050","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1093\/cid\/ciq257","article-title":"International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases","volume":"52","author":"Gupta","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.10.010_bib0055","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1186\/s12879-014-0628-7","article-title":"Review of the literature and individual patients' data meta-analysis on efficacy and tolerance of nitroxoline in the treatment of uncomplicated urinary tract infections","volume":"14","author":"Naber","year":"2014","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.10.010_bib0060","doi-asserted-by":"crossref","first-page":"477","DOI":"10.4103\/0255-0857.167350","article-title":"Advantage and limitations of nitrofurantoin in multi-drug resistant Indian scenario","volume":"33","author":"Shakti","year":"2015","journal-title":"Indian J Med Microbiol"},{"key":"10.1016\/j.ijantimicag.2017.10.010_bib0065","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.4065\/80.10.1298","article-title":"Chronic nitrofurantoin-induced lung disease","volume":"80","author":"Mendez","year":"2005","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ijantimicag.2017.10.010_bib0070","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/qjmed\/hcs129","article-title":"Lung toxicity and nitrofurantoin: the tip of the iceberg?","volume":"106","author":"Weir","year":"2013","journal-title":"QJM"},{"key":"10.1016\/j.ijantimicag.2017.10.010_bib0075","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/SMJ.0000000000000059","article-title":"Nitrofurantoin-induced hepatotoxicity: a rare yet serious complication","volume":"107","author":"Sakaan","year":"2014","journal-title":"South Med J"},{"key":"10.1016\/j.ijantimicag.2017.10.010_bib0080","first-page":"758","article-title":"Fatal nitrofurantoin lung","volume":"61","author":"Mullerpattan","year":"2013","journal-title":"J Assoc Physicians India"},{"key":"10.1016\/j.ijantimicag.2017.10.010_bib0085","doi-asserted-by":"crossref","first-page":"6021","DOI":"10.1128\/AAC.01484-12","article-title":"The urinary antibiotic 5-nitro-8-hydroxyquinoline (nitroxoline) reduces the formation and induces the dispersal of Pseudomonas aeruginosa biofilms by chelation of iron and zinc","volume":"56","author":"Sobke","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.10.010_bib0090","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1128\/AAC.39.3.707","article-title":"Roles of divalent cations and pH in mechanism of action of nitroxoline against Escherichia coli strains","volume":"39","author":"Pelletier","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.10.010_bib0095","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1007\/s00120-017-0389-1","article-title":"Epidemiology, diagnostics, therapy, prevention and management of uncomplicated bacterial outpatient acquired urinary tract infections in adult patients: update 2017 of the interdisciplinary AWMF S3 guideline","volume":"56","author":"Kranz","year":"2017","journal-title":"Urologe A"},{"key":"10.1016\/j.ijantimicag.2017.10.010_bib0100","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/infdis\/133.1.14","article-title":"Inhibition of the antibacterial activity of gentamicin by urine","volume":"133","author":"Minuth","year":"1976","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.10.010_bib0105","doi-asserted-by":"crossref","first-page":"7019","DOI":"10.1128\/AAC.03946-14","article-title":"In vitro activity of nitroxoline against Escherichia coli urine isolates from outpatient departments in Germany","volume":"58","author":"Kresken","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.10.010_bib0110","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.eururo.2008.05.010","article-title":"Surveillance study in Europe and Brazil on clinical aspects and Antimicrobial Resistance Epidemiology in Females with Cystitis (ARESC): implications for empiric therapy","volume":"54","author":"Naber","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.ijantimicag.2017.10.010_bib0115","doi-asserted-by":"crossref","first-page":"923","DOI":"10.4269\/ajtmh.2011.11-0057","article-title":"Decreased susceptibility to commonly used antimicrobial agents in bacterial pathogens isolated from urinary tract infections in Rwanda: need for new antimicrobial guidelines","volume":"84","author":"Muvunyi","year":"2011","journal-title":"Am J Trop Med Hyg"},{"issue":"Suppl. A","key":"10.1016\/j.ijantimicag.2017.10.010_bib0120","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/jac\/46.suppl_1.49","article-title":"Survey on antibiotic usage in the treatment of urinary tract infections","volume":"46","author":"Naber","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2017.10.010_bib0125","doi-asserted-by":"crossref","first-page":"e47707","DOI":"10.1371\/journal.pone.0047707","article-title":"Antimicrobial resistance and spread of multi drug resistant Escherichia coli isolates collected from nine urology services in the Euregion Meuse-Rhine","volume":"7","author":"van der Donk","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ijantimicag.2017.10.010_bib0130","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1128\/jb.104.3.1126-1134.1970","article-title":"Mode of action of nitrofurazone","volume":"104","author":"McCalla","year":"1970","journal-title":"J Bacteriol"},{"key":"10.1016\/j.ijantimicag.2017.10.010_bib0135","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/jac\/dkn222","article-title":"Nitrofurantoin resistance mechanism and fitness cost in Escherichia coli","volume":"62","author":"Sandegren","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2017.10.010_bib0140","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1128\/AAC.06060-11","article-title":"In vitro antimicrobial resistance of urinary Escherichia coli isolates among U.S. outpatients from 2000 to 2010","volume":"56","author":"Sanchez","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.10.010_bib0145","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.diagmicrobio.2009.03.027","article-title":"Antimicrobial resistance among uropathogens that cause acute uncomplicated cystitis in women in Hong Kong: a prospective multicenter study in 2006 to 2008","volume":"66","author":"Ho","year":"2010","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.10.010_bib0150","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s15010-011-0132-6","article-title":"Extended-spectrum \u03b2-lactamase-producing Gram-negative pathogens in community-acquired urinary tract infections: an increasing challenge for antimicrobial therapy","volume":"39","author":"Meier","year":"2011","journal-title":"Infection"},{"key":"10.1016\/j.ijantimicag.2017.10.010_bib0155","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ijantimicag.2006.08.039","article-title":"Fosfomycin in the treatment of extended spectrum \u03b2-lactamase-producing Escherichia coli-related lower urinary tract infections","volume":"29","author":"Pullukcu","year":"2007","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2017.10.010_bib0160","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1093\/jac\/12.5.459","article-title":"Transferable nitrofuran resistance conferred by R-plasmids in clinical isolates of Escherichia coli","volume":"12","author":"Breeze","year":"1983","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2017.10.010_bib0165","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1016\/S0022-5347(05)64397-2","article-title":"Resistance trends in urinary tract pathogens and impact on management","volume":"168","author":"Mazzulli","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.ijantimicag.2017.10.010_bib0170","first-page":"959","article-title":"Antibacterial activity of nitroxoline and sulphamethizole alone and in combination in urinary tract infections","volume":"54","author":"Jacobs","year":"1978","journal-title":"S Afr Med J"},{"key":"10.1016\/j.ijantimicag.2017.10.010_bib0175","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1128\/AAC.02147-13","article-title":"Urinary concentrations and antibacterial activities of nitroxoline at 250 milligrams versus trimethoprim at 200 milligrams against uropathogens in healthy volunteers","volume":"58","author":"Wagenlehner","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.10.010_bib0180","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.ijantimicag.2017.01.005","article-title":"Effects of colistin on biofilm matrices of Escherichia coli and Staphylococcus aureus","volume":"49","author":"Klinger-Strobel","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2017.10.010_bib0185","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1042\/bj0410529","article-title":"The choice of a chelating agent for inactivating trace metals; a survey of commercially available chelating agents","volume":"41","author":"Albert","year":"1947","journal-title":"Biochem J"},{"key":"10.1016\/j.ijantimicag.2017.10.010_bib0190","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1128\/jb.138.3.923-932.1979","article-title":"Transient growth inhibition of Escherichia coli K-12 by ion chelators: \u2018in vivo\u2019 inhibition of ribonucleic acid synthesis","volume":"138","author":"Collins","year":"1979","journal-title":"J Bacteriol"},{"key":"10.1016\/j.ijantimicag.2017.10.010_bib0195","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1136\/pgmj.66.779.727","article-title":"Relationship of urinary pH to symptoms of \u2018cystitis\u2019","volume":"66","author":"Brumfitt","year":"1990","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.ijantimicag.2017.10.010_bib0200","unstructured":"Forstner C., Kwetkat A., Makarewicz O., Hartung A., Pfister W., Funfstuck R., et\u00a0al. Nitroxoline in geriatric patients with lower urinary tract infection fails to achieve microbiologic eradication: a noncomparative, prospective observational study. Clin Microbiol Infect in press."}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857917303746?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857917303746?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,3]],"date-time":"2022-07-03T15:54:00Z","timestamp":1656863640000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857917303746"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["S0924857917303746"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2017.10.010","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Empirical treatment of lower urinary tract infections in the face of spreading multidrug resistance: in vitro study on the effectiveness of nitroxoline","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2017.10.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}